Background A proliferation-inducing ligand (APRIL) is implicated in the pathogenesis of IgA
nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and …

Objective: Recent outcomes enhanced the critical role of glycosylation pattern of
autoantibodies in the pathophysiology of antibody-mediated autoimmune diseases. In this …

Glomerulonephritis (GN) is a group of heterogeneous immune-mediated kidney diseases
that causes inflammation within the glomerulus. Autoantibodies (auto-Abs) are considered to …

Background IgA nephropathy is thought to be an autoimmune disease wherein galactose-
deficient IgA1 (Gd-IgA1) is recognized by IgG autoantibodies, resulting in formation and …

IgA nephropathy (IgAN) is the most prevalent primary chronic glomerular disease for which
no safe disease-specific therapies currently exist. IgAN is an autoimmune disease involving …

Dysregulation of mucosal immunity may play a role in the pathogenesis of IgA nephropathy
(IgAN). However, it is unclear whether the nasal-associated lymphoid tissue (NALT) or gut …

Background Recent studies have shown that galactose-deficient IgA1 (GdIgA1) has an
important role in the pathogenesis of IgA nephropathy (IgAN). Although emerging data …

IgA nephropathy (IgAN) is a progressive disease with great variability in the clinical course.
Among the clinical and pathologic features contributing to variable outcomes, the presence …

IgA nephropathy is the most common primary glomerulonephritis worldwide and carries a
substantial risk of kidney failure. New agency-approved therapies, either specifically for IgA …

The progression determinants of IgA nephropathy (IgAN) are still not fully elucidated. We
have previously demonstrated that the mucosal activation of toll-like receptor (TLR) 9, which …